North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023

List of Tables

The North America Oncology Drugs Market would witness market growth of 6.8% CAGR during the forecast period (2023-2030).

Cancer appears as the third most lethal disease globally, following infectious, parasitic, and cardiovascular diseases. Chemoprevention is a pharmacological approach that employs naturally occurring or synthetic compounds to prevent or impede cancer development. The treatment of cancer consists of medicines, radiation, and surgery. Surgical intervention is the initial course of action when early-stage cancer is diagnosed. The final one, chemotherapy (CTX), involves administering various pharmaceuticals with cytotoxic properties. Targeted therapy is a cancer treatment that precisely targets the modifications that facilitate cancer cells' growth, division, and metastasis.

As a form of cancer treatment, immunotherapy stimulates the immune system to combat the disease. Hormone therapy inhibits or eradicates the proliferation of prostate and breast malignancies, which are metastasized by hormones. Anticancer medications exhibit reduced selectivity towards cancer cells while impeding cell division and proliferation. Consequently, these medications eradicate not only malignant cells but also healthy cells. Chemotherapy or anticancer drugs are chemical substances that inhibit the development of cancer cells by denaturing them. Although anticancer medicines inhibit the division of cancer cells, the process also impacts healthy cells.

North America is a hub for pharmaceutical and biotechnology companies conducting cutting-edge research in oncology. The region's emphasis on R&D innovation has led to the developing novel cancer drugs, including targeted therapies, immunotherapies, and precision medicine approaches. Lung and bronchus cancer have consistently been among the most commonly analyzed cancers and leading causes of cancer-related deaths in the United States. The rising incidence and mortality rates highlight the urgent need for effective oncology drugs to treat and manage this disease. The above aspects will expand the market growth across the region in the upcoming years.

The US region dominated the North America Oncology Drugs Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $71,596.5 million by 2030. The Canada region is experiencing a CAGR of 9.2% during (2023 - 2030). Additionally, The Mexico region would exhibit a CAGR of 8.2% during (2023 - 2030).

Based on Indication, the market is segmented into Breast Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Colorectal Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancer. Based on Drug Class Type, the market is segmented into Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.

Scope of the Study

Market Segments covered in the Report:

By Indication

Breast Cancer
Prostate Cancer
Lung Cancer
Stomach Cancer
Colorectal Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancer

By Drug Class Type

Targeted Therapy
Immunotherapy (Biologic Therapy)
Chemotherapy
Hormonal Therapy

By Country

US
Canada
Mexico
Rest of North America

Companies Profiled

AbbVie, Inc.
Amgen, Inc.
Astellas Pharma, Inc.
AstraZeneca PLC
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Novartis AG
Merck & Co., Inc.
Pfizer Inc.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 North America Oncology Drugs Market, by Indication
- 1.4.2 North America Oncology Drugs Market, by Drug Class Type
- 1.4.3 North America Oncology Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global

4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
- 4.2.1 Partnerships, Collaborations and Agreements
- 4.2.2 Product Launches and Product Expansions
- 4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
- 4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar - 2023, Nov) Leading Players
4.4 Porter's Five Forces Analysis

Chapter 5. North America Oncology Drugs Market by Indication

5.1 North America Breast Cancer Market by Country
5.2 North America Prostate Cancer Market by Country
5.3 North America Lung Cancer Market by Country
5.4 North America Stomach Cancer Market by Country
5.5 North America Colorectal Cancer Market by Country
5.6 North America Liver Cancer Market by Country
5.7 North America Esophagus Cancer Market by Country
5.8 North America Cervical Cancer Market by Country
5.9 North America Kidney Cancer Market by Country
5.10. North America Bladder Cancer Market by Country
5.11 North America Other Cancer Market by Country

Chapter 6. North America Oncology Drugs Market by Drug Class Type

6.1 North America Targeted Therapy Market by Country
6.2 North America Immunotherapy (Biologic Therapy) Market by Country
6.3 North America Chemotherapy Market by Country
6.4 North America Hormonal Therapy Market by Country

Chapter 7. North America Oncology Drugs Market by Country

7.1 US Oncology Drugs Market
- 7.1.1 US Oncology Drugs Market by Indication
- 7.1.2 US Oncology Drugs Market by Drug Class Type
7.2 Canada Oncology Drugs Market
- 7.2.1 Canada Oncology Drugs Market by Indication
- 7.2.2 Canada Oncology Drugs Market by Drug Class Type
7.3 Mexico Oncology Drugs Market
- 7.3.1 Mexico Oncology Drugs Market by Indication
- 7.3.2 Mexico Oncology Drugs Market by Drug Class Type
7.4 Rest of North America Oncology Drugs Market
- 7.4.1 Rest of North America Oncology Drugs Market by Indication
- 7.4.2 Rest of North America Oncology Drugs Market by Drug Class Type

Chapter 8. Company Profiles

8.1 AbbVie, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 Recent strategies and developments:
  - 8.1.5.1 Partnerships, Collaborations, and Agreements:
  - 8.1.5.2 Acquisition and Mergers:
- 8.1.6 SWOT Analysis
8.2 Amgen, Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
  - 8.2.5.1 Acquisition and Mergers:
- 8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
  - 8.3.5.1 Partnerships, Collaborations, and Agreements:
  - 8.3.5.2 Acquisition and Mergers:
- 8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.4.5 Recent strategies and developments:
  - 8.4.5.1 Partnerships, Collaborations, and Agreements:
  - 8.4.5.2 Product Launches and Product Expansions:
- 8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Partnerships, Collaborations, and Agreements:
  - 8.5.5.2 Product Launches and Product Expansions:
  - 8.5.5.3 Acquisition and Mergers:
- 8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 Research & Development Expense
- 8.6.5 Recent strategies and developments:
  - 8.6.5.1 Partnerships, Collaborations, and Agreements:
  - 8.6.5.2 Product Launches and Product Expansions:
  - 8.6.5.3 Acquisition and Mergers:
- 8.6.6 SWOT Analysis
8.7 Johnson & Johnson
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental & Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
  - 8.7.5.1 Partnerships, Collaborations, and Agreements:
  - 8.7.5.2 Acquisition and Mergers:
- 8.7.6 SWOT Analysis
8.8 Novartis AG
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
  - 8.8.5.1 Partnerships, Collaborations, and Agreements:
- 8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expenses
- 8.9.5 Recent strategies and developments:
  - 8.9.5.1 Partnerships, Collaborations, and Agreements:
  - 8.9.5.2 Acquisition and Mergers:
- 8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional & Segmental Analysis
- 8.10.4 Research & Development Expense
- 8.10.5 Recent strategies and developments:
  - 8.10.5.1 Partnerships, Collaborations, and Agreements:
- 8.10.6 SWOT Analysis

LIST OF TABLES

TABLE 1 North America Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 2 North America Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Oncology Drugs Market
TABLE 4 Product Launches And Product Expansions- Oncology Drugs Market
TABLE 5 Acquisition and Mergers- Oncology Drugs Market
TABLE 6 North America Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 7 North America Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 8 North America Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 North America Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 North America Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 11 North America Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 12 North America Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 13 North America Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 14 North America Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 15 North America Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 16 North America Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 17 North America Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 18 North America Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 19 North America Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 20 North America Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 21 North America Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 22 North America Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 23 North America Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 24 North America Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 25 North America Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 26 North America Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 27 North America Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 28 North America Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 29 North America Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 30 North America Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 31 North America Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 32 North America Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 33 North America Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 34 North America Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 35 North America Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 36 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 37 North America Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 38 North America Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 39 North America Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 40 North America Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 41 North America Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 42 US Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 43 US Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 44 US Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 45 US Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 46 US Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 47 US Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 48 Canada Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 49 Canada Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 50 Canada Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 51 Canada Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 52 Canada Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 53 Canada Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 54 Mexico Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 55 Mexico Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 56 Mexico Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 57 Mexico Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 58 Mexico Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 59 Mexico Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 60 Rest of North America Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 61 Rest of North America Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 62 Rest of North America Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 63 Rest of North America Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 64 Rest of North America Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 65 Rest of North America Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 66 Key information - AbbVie, Inc.
TABLE 67 Key Information - Amgen, Inc.
TABLE 68 key information - Astellas Pharma, Inc.
TABLE 69 KEY INFORMATION - AstraZeneca PLC
TABLE 70 Key Information - Bristol Myers Squibb Company
TABLE 71 Key Information - F. Hoffmann-La Roche Ltd.
TABLE 72 Key Information - Johnson & Johnson
TABLE 73 Key Information - Novartis AG
TABLE 74 Key Information - Merck & Co., Inc.
TABLE 75 Key Information - Pfizer, Inc.

North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents